Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status
暂无分享,去创建一个
Q. Sun | Jiaqi Liu | Yidong Zhou | Xin Huang | X. Cao | Ying Xu | R. Yao | Chang Chen | Xiang Wang
[1] M. Somerfield,et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Feiran Wang,et al. Clinical value of postoperative sentinel lymph node biopsy. , 2019, Annals of translational medicine.
[3] Huang Li,et al. Factors that affect the false negative rate of sentinel lymph node mapping with methylene blue dye alone in breast cancer , 2019, The Journal of international medical research.
[4] C. Colin,et al. Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities. , 2019, Radiology.
[5] R. Tollenaar,et al. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. , 2019, Annals of surgery.
[6] Yuntao Xie,et al. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China , 2019, Breast Cancer Research and Treatment.
[7] R. Gelber,et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.
[8] Stephen Broderick,et al. Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.
[9] A. Taghian,et al. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. , 2018, Gland surgery.
[10] T. Munyombwe,et al. Preoperative sentinel lymph node identification, biopsy and localisation using contrast enhanced ultrasound (CEUS) in patients with breast cancer: a systematic review and meta-analysis. , 2017, Clinical radiology.
[11] A. Giuliano,et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial , 2017, JAMA.
[12] R. Tollenaar,et al. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women , 2017, Journal of the National Cancer Institute.
[13] L. Boersma,et al. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08) , 2017, BMC Cancer.
[14] W. Chung,et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.
[15] B. Wörmann. Breast cancer: basics, screening, diagnostics and treatment. , 2017, Medizinische Monatsschrift fur Pharmazeuten.
[16] A. Hauschild,et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.
[17] Chong Geng,et al. The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis , 2016, PloS one.
[18] K. Hunt,et al. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) , 2016, Annals of surgery.
[19] N. Biglia,et al. Breast cancer treatment in mutation carriers: surgical treatment. , 2016, Minerva ginecologica.
[20] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[21] E. Lambaudie,et al. [Sentinel lymph node-multicentric and multifocal tumors: a valid technique?]. , 2015, Gynecologie, obstetrique & fertilite.
[22] J. Wolchok,et al. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. , 2015, The New England journal of medicine.
[23] I. Melero,et al. Genetic basis for clinical response to CTLA-4 blockade. , 2015, The New England journal of medicine.
[24] Å. Borg,et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer , 2014, Breast Cancer Research and Treatment.
[25] S. Edge,et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Francesco Giammarile,et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[27] J. Lubiński,et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Powell,et al. BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.
[29] M. Brennan,et al. Accuracy of sentinel lymph node biopsy in large and multifocal/multicentric breast carcinoma--a systematic review. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[30] R. Wiatrek,et al. Sentinel lymph node biopsy indications and controversies in breast cancer. , 2011, Maturitas.
[31] A. Giuliano,et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.
[32] K. Griffith,et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy , 2010, Breast Cancer Research and Treatment.
[33] A. Luini,et al. Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study , 2010, Annals of surgery.
[34] A. Luini,et al. Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer? , 2009, Annals of Surgical Oncology.
[35] T. Julian,et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. , 2007, The Lancet. Oncology.
[36] U. Chetty,et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. , 2006, Journal of the National Cancer Institute.
[37] E. Winer,et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[39] M. Morrow,et al. Appropriateness of Breast-Conserving Treatment of Breast Carcinoma in Women With Germline Mutations in BRCA1 or BRCA2: A Clinic-Based SeriesRobson M, Svahn T, McCormick B, et al (Mem Sloan-Kettering Cancer Ctr, New York) Cancer 103:44-51, 2005§ , 2006 .
[40] J. Bryant,et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. , 2002, Cancer.